Last reviewed · How we verify
medical cannabis
Medical cannabis exerts its effects through the body's endocannabinoid system, influencing various physiological processes.
Medical cannabis exerts its effects through the body's endocannabinoid system, influencing various physiological processes. Used for Chronic pain, Nausea and vomiting associated with chemotherapy, Muscle spasms.
At a glance
| Generic name | medical cannabis |
|---|---|
| Also known as | medical marijuana, medicinal cannabinoids (MCBD), CBD/THC, Cannabis oil containing 10% delta-9-tetrahydrocannabinol (THC) and 5% cannabidiol (CBD) |
| Sponsor | HaEmek Medical Center, Israel |
| Target | CB1 and CB2 receptors |
| Modality | Small molecule |
| Therapeutic area | Pain management, Nausea and vomiting, Muscle spasms |
| Phase | Phase 3 |
Mechanism of action
The endocannabinoid system is a complex network of receptors and chemicals that play a crucial role in regulating functions such as pain, mood, and memory. Medical cannabis interacts with this system, producing therapeutic effects in conditions like chronic pain, nausea, and muscle spasms.
Approved indications
- Chronic pain
- Nausea and vomiting associated with chemotherapy
- Muscle spasms
Common side effects
- Dry mouth
- Dizziness
- Fatigue
Key clinical trials
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
- Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1) (NA)
- Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NA)
- Medical Cannabis During Chemoradiation for Head and Neck Cancer
- Community Based Cannabis Cessation Program
- Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients
- Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- medical cannabis CI brief — competitive landscape report
- medical cannabis updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI